Teleflex Inc is a global provider of medical technology products that enhance the ability of healthcare professionals to provide high-quality patient care. The company develops a wide range of innovative solutions across various medical specialties, including surgical, critical care, and respiratory applications. Teleflex focuses on the design, manufacturing, and commercialization of devices and instruments that improve procedural outcomes, facilitate patient recovery, and enhance safety in both hospital and outpatient settings. With a commitment to advancing medical technologies, Teleflex aims to meet the evolving needs of healthcare providers and patients worldwide. Read More
Shares of medical technology company Teleflex (NYSE:TFX)
fell 15.5% in the morning session after the company reported underwhelming earnings. The medical technology firm's operating margin collapsed to negative 44.8%, a stark reversal from the positive 19.5% margin recorded in the same quarter a year ago. This dramatic 64.3 percentage point drop indicated that the company’s expenses grew much faster than its revenue. Adding to the concerns, Teleflex's cash generation also weakened significantly, with its free cash flow margin falling to 8.5% from 27.5% in the prior year's quarter. While the company beat headline estimates and reiterated its full-year adjusted earnings guidance, the sharp decline in underlying profitability and cash flow appears to have alarmed investors, prompting a major sell-off.
Medical technology company Teleflex (NYSE:TFX) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 19.4% year on year to $913 million. Its non-GAAP profit of $3.67 per share was 8.6% above analysts’ consensus estimates.
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 15, 2025, to shareholders of record at the close of business on November 14, 2025.
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 28, 2025.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Discover Teleflex Inc (TFX), an undervalued stock with strong financials, solid profitability, and a low P/E ratio, offering a potential margin of safety for value investors.
WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Shares of medical technology company Teleflex (NYSE:TFX)
fell 5.4% in the afternoon session after the U.S. government launched a probe into the medical device industry.
Teleflex Inc (TFX) appears undervalued with a low P/E ratio, strong profitability, solid financial health, and positive growth forecasts, making it a compelling stock for value investors.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at surgical equipment & consumables - specialty stocks, starting with Teleflex (NYSE:TFX).
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p.m. (ET).
Discover Teleflex Inc. (TFX), an undervalued medical tech stock with strong fundamentals, solid profitability, and a compelling valuation for value investors.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 7.1%. This drawdown is a far cry from the S&P 500’s 4.7% ascent.
Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan.
Medical technology company Teleflex (NYSE:TFX) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.3% year on year to $780.9 million. Its non-GAAP profit of $3.73 per share was 10.8% above analysts’ consensus estimates.
A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
